Sanyou Bio and Baiyunshan Xihe Partner on Radiopharmaceutical Development
Sanyou Biopharmaceutical Co., Ltd. and Guangzhou Baiyunshan Xihe Health Pharmaceutical Co., Ltd. have signed a strategic cooperation agreement to advance radiopharmaceutical and radiodiagnostic technologies.
Shanghai-based Sanyou Bio and Guangzhou-based Baiyunshan Xihe officially announced a strategic collaboration on July 4, 2026, aimed at developing innovative radiopharmaceuticals and radiodiagnostics. The agreement marks a significant step for both companies in the specialized field of nuclear medicine.
The partnership intends to leverage Sanyou Bio's expertise in biological drugs and Baiyunshan Xihe's capabilities in pharmaceutical manufacturing and distribution. This synergy is expected to accelerate the research, development, and commercialization of new diagnostic and therapeutic agents for various medical conditions.
Radiopharmaceuticals are used in both the diagnosis and treatment of diseases, particularly in oncology. The collaboration will focus on creating novel agents that can improve treatment efficacy and patient outcomes. Specific details regarding the initial projects or target diseases were not disclosed.
This initiative places both companies within a growing segment of the pharmaceutical industry focused on precision medicine and advanced imaging techniques. The agreement underscores a shared commitment to addressing unmet medical needs through technological advancement in a highly specialized area of healthcare.